Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

5132 - Outcomes of intracranial stereotactic radiotherapy (SRT) in metastatic breast cancer (BC)

Date

11 Sep 2017

Session

Poster display session

Topics

Surgical Oncology;  Radiation Oncology;  Breast Cancer

Presenters

Gargi Kothari

Citation

Annals of Oncology (2017) 28 (suppl_5): v74-v108. 10.1093/annonc/mdx365

Authors

G. Kothari1, K. Mohammed2, G. Ross1

Author affiliations

  • 1 Breast Unit, Royal Marsden Hospital NHS Foundation Trust, SW3 6JJ - London/GB
  • 2 Research And Development Department, The Royal Marsden NHS Foundation Trust, SW3 6JJ - London/GB
More

Resources

Abstract 5132

Background

Brain metastases (BM) are a significant cause of morbidity and mortality. Advancement of systemic therapies for patients with BC has improved control of extra-cranial metastases and survival. Intracranial control however continues to be challenging. SRT has been shown to provide excellent local control (LC) with minimal toxicity, although breast specific data is comparatively lacking.

Methods

This study aims to describe outcomes of first SRT including LC, distant brain control (DC), time to intracranial progression (TTP) and overall survival (OS) in a cohort of patients with BC who received SRT from 2001 to 2016 at the Royal Marsden Hospital. Kaplan Meier and log-rank methods were used for statistical analysis.

Results

64 patients underwent SRT for 129 BM. Median age was 52.4 years. 58 (91%) were ECOG 0/1. 18 (28%) were hormone receptor positive (HR+)/HER-2 negative, 38 (59%) were HER-2 enriched (HER-2+), and 8 (13%) were triple negative (TN). The median number of BM treated with SRT was 1 (range 1 - 12). Median dose and range was 20 Gy (12 – 35 Gy) in 1 fraction (1 – 10). 29 (45%) were treated using a linear accelerator, 34 (53%) with CyberKnife and 1 with GammaKnife. 27 (42%) had prior whole or partial brain radiotherapy (WBRT). 21 (33%) had prior surgery. 30 (49%) had concurrent endocrine therapy, 25 (40%) had targeted therapy and 8 (13%) had chemotherapy. Follow-up imaging was available for 57 patients. Median follow up was 15 months. 1 year LC was 54% and DC was 56%. Median TTP was 7.1 months (95%CI: 6.1 – 10.8) and was significantly worse for TN compared to HER-2+ patients (5.3 vs 9.9 months, p = 0.046). Salvage radiotherapy or surgery was performed after SRT in 13 (23%) patients for local failure, and 20 (35%) for distant failure. 7 (12%) patients had radionecrosis following SRT. OS from SRT was 19.6 months (95%CI: 14.9 – 23.1), and was significantly worse for TN patients (13.6 vs 22.1 months, p = 0.003), age ≥ 60 years (14.9 vs 19.8 months, p = 0.028) and multiple brain metastases (14.0 vs 22.6 months, p = 0.010).

Conclusions

Outcomes in patients with BC and BM treated with SRT are excellent overall. Outcomes are worse in TN disease, older patients and patients with multiple BM, and should be considered in SRT decision making.

Clinical trial identification

Legal entity responsible for the study

The Royal Marsden NHS Foundation Trust

Funding

The Royal Marsden NHS Foundation Trust/Ross Smith Cridlan Trust

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.